| INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease PF Meyer, J Tremblay-Mercier, J Leoutsakos, C Madjar, ... Neurology 92 (18), e2070-e2080, 2019 | 127 | 2019 |
| Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography PF Meyer, AP Binette, J Gonneaud, JCS Breitner, S Villeneuve, ... JAMA neurology 77 (4), 508-516, 2020 | 87 | 2020 |
| Amyloid and tau pathology associations with personality traits, neuropsychiatric symptoms, and cognitive lifestyle in the preclinical phases of sporadic and autosomal dominant … AP Binette, É Vachon-Presseau, J Morris, R Bateman, T Benzinger, ... Biological psychiatry 89 (8), 776-785, 2021 | 47 | 2021 |
| Plasma p‐tau231, p‐tau181, PET biomarkers, and cognitive change in older adults PF Meyer, NJ Ashton, TK Karikari, C Strikwerda‐Brown, T Köbe, ... Annals of neurology 91 (4), 548-560, 2022 | 46 | 2022 |
| Bi-directional association of cerebrospinal fluid immune markers with stage of Alzheimer’s disease pathogenesis PF Meyer, M Savard, J Poirier, A Labonte, P Rosa-Neto, TM Weitz, ... Journal of Alzheimer's Disease 63 (2), 577-590, 2018 | 41 | 2018 |
| Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults M McSweeney, A Pichet Binette, PF Meyer, J Gonneaud, C Bedetti, ... Neurology 94 (11), e1190-e1200, 2020 | 35 | 2020 |
| New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin … A Begemann, H Sticht, A Begtrup, A Vitobello, L Faivre, S Banka, ... Genetics in Medicine 23 (3), 543-554, 2021 | 34 | 2021 |
| Association of vascular risk factors with β-amyloid peptide and tau burdens in cognitively unimpaired individuals and its interaction with vascular medication use T Köbe, J Gonneaud, AP Binette, PF Meyer, M McSweeney, P Rosa-Neto, ... JAMA network open 3 (2), e1920780-e1920780, 2020 | 32 | 2020 |
| Dementia risk reduction: why haven't the pharmacological risk reduction trials worked? An in‐depth exploration of seven established risk factors R Peters, J Breitner, S James, GA Jicha, PF Meyer, M Richards, AD Smith, ... Alzheimer's & Dementia: Translational Research & Clinical Interventions 7 (1 …, 2021 | 20 | 2021 |
| Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. Association of vascular risk factors with β-Amyloid peptide and … T Köbe, J Gonneaud, A Pichet Binette, PF Meyer, M McSweeney, ... JAMA Netw. Open 3, e1920780, 2020 | 14 | 2020 |
| Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology PF Meyer, M Savard, J Poirier, D Morgan, J Breitner, ... Alzheimer's & Dementia 15 (9), 1160-1171, 2019 | 12 | 2019 |
| AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention PF Meyer, M McSweeney, J Gonneaud, S Villeneuve Progress in molecular biology and translational science 165, 63-106, 2019 | 11 | 2019 |
| No apparent effect of naproxen on CSF markers of innate immune activation PF Meyer, A Labonté, P Rosa‐Neto, J Poirier, JCS Breitner, ... Annals of clinical and translational neurology 6 (6), 1127-1133, 2019 | 10 | 2019 |
| Spatial extent of amyloid-β levels and associations with tau-PET and cognition H Ozlen, AP Binette, T Köbe, PF Meyer, J Gonneaud, F St-Onge, ... JAMA neurology 79 (10), 1025-1035, 2022 | 9 | 2022 |
| Acoustic shadows detection, application to accurate reconstruction of 3D intraoperative ultrasound P Hellier, P Coupé, P Meyer, X Morandi, DL Collins 2008 5th IEEE International Symposium on Biomedical Imaging: From Nano to …, 2008 | 9 | 2008 |
| Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease Y Yakoub, NJ Ashton, C Strikwerda‐Brown, L Montoliu‐Gaya, TK Karikari, ... Alzheimer's & Dementia 19 (12), 5620-5631, 2023 | 8 | 2023 |
| The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here? R Peters, HH Dodge, S James, GA Jicha, PF Meyer, M Richards, ... Alzheimer's & Dementia 18 (3), 507-512, 2022 | 7 | 2022 |
| Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) research group. Plasma p-tau231, p-tau181, PET Biomarkers, and cognitive change … PF Meyer, NJ Ashton, TK Karikari Ann Neurol 91 (4), 548-560, 2022 | 7 | 2022 |
| Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular … T Köbe, AP Binette, JW Vogel, PF Meyer, JCS Breitner, J Poirier, ... Neuroimage 231, 117832, 2021 | 7 | 2021 |
| Author response: INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease J Breitner, PF Meyer Neurology 94 (13), 594-594, 2020 | 6 | 2020 |
